Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy

Fujimura, Taku; Kambayashi, Yahiko; Ohuchi, Kentaro; Amagai, Ryo; Sato, Yota; Tanita, Kayo; Hashimoto, Akira; Aiba, Setsuya

doi:10.1159/000506327

Cited by 4 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this case, the patient was offered this cocktail of immunotherapy; however, her pregnancy complicated matters. There have been a few case reports in which nivolumab or ipilimumab with denosumab have been shown to be effective in the treatment of mucosal melanomas [ 13 , 14 ]. Such immunotherapy has been classified as pregnancy category D by the Food and Drug Administration, which means that the drugs in this class may be used in pregnancy if the benefits to the mother outweigh the risk to the fetus [ 13 , 14 ].…”

Section: Discussionmentioning

confidence: 99%

“…There have been a few case reports in which nivolumab or ipilimumab with denosumab have been shown to be effective in the treatment of mucosal melanomas [ 13 , 14 ]. Such immunotherapy has been classified as pregnancy category D by the Food and Drug Administration, which means that the drugs in this class may be used in pregnancy if the benefits to the mother outweigh the risk to the fetus [ 13 , 14 ]. As a result, immune checkpoint inhibitors are discouraged during pregnancy, as one case series showed that 88.9% of pregnant patients on immunotherapy had premature onset of labor, while 71.4% had other complications such as intrauterine growth restriction, placental insufficiency, and lower fetal heart rates [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Primary Mucosal Melanoma of the Lip With GNA11 Mutation in a 23-Year-Old Pregnant Woman

Khatri¹,

Kashfi²,

Griffin³

2023

Cureus

View full text Add to dashboard Cite

Mucosal melanoma represents a small proportion of all melanoma cases and is associated with a worse prognosis. Primary malignant melanoma of the lip (PMML) is far less common, and only a few cases have been reported since 1997, most commonly in China, Japan, Uganda, and India. Most of these cases have been associated with the gene C-KIT. As a result, treatment guidelines surrounding mucosal melanoma are unclear, especially in complicated populations such as pregnant women. Mutations in theGNAQ and GNA11 genes have been found to be associated with uveal melanoma, while they are rarely associated with mucosal melanoma. We present the case of a 23-year-old pregnant woman who was found to have likely primary malignant melanoma of the lip that metastasized to the left jaw, neck, breast, lungs, and ovaries and was found to be positive for both the BRAF-MLL3 and GNA11 mutation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Primary Mucosal Melanoma of the Lip With GNA11 Mutation in a 23-Year-Old Pregnant Woman

Khatri¹,

Kashfi²,

Griffin³

2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Although most melanoma tumors develop in the skin (cutaneous melanoma), they can also arise in mucosal membranes, [10][11][12][13][14][15][16][17], in the eye (uveal melanoma) [18], and primary melanoma tumors have also been described in leptomeninges (Table 1) [19]. Among these different types of melanoma, cutaneous melanoma is by far the most prevalent.…”

Section: Cutaneous and Non-cutaneous Melanomamentioning

confidence: 99%

RAGE Signaling in Melanoma Tumors

Olaoba

Kadasah

Vetter

et al. 2020

IJMS

View full text Add to dashboard Cite

Despite recent progresses in its treatment, malignant cutaneous melanoma remains a cancer with very poor prognosis. Emerging evidences suggest that the receptor for advance glycation end products (RAGE) plays a key role in melanoma progression through its activation in both cancer and stromal cells. In tumors, RAGE activation is fueled by numerous ligands, S100B and HMGB1 being the most notable, but the role of many other ligands is not well understood and should not be underappreciated. Here, we provide a review of the current role of RAGE in melanoma and conclude that targeting RAGE in melanoma could be an approach to improve the outcomes of melanoma patients.

show abstract

“…As yet, the available evidence for ICI is based on single case reports, retrospective analyses and small study subpopulations in clinical trials. In two published cases of metastatic mucosal melanoma, a complete remission was seen following Nivolumab, Ipilimumab plus Denosumab combination therapy [ 19 ] and Nivolumab monotherapy [ 20 ], respectively. In a pooled analysis from six prospective clinical trials, the data of 157 patients with unresectable or metastatic mucosal melanoma were analyzed.…”

Section: Introductionmentioning

confidence: 99%

Multimodal treatment and immune checkpoint inhibition in sinonasal mucosal melanoma: real-world data of a retrospective, single-center study

Scherzad

Stöth

Meyer

et al. 2023

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Purpose Local failure and distant metastases occur frequently in sinonasal mucosal melanoma (SNMM). Response rates to chemotherapy are low and targetable mutations are rarely detected. However, there is increasing data indicating efficacy of immune checkpoint inhibition (ICI). The aim of this retrospective monocenter study was to assess the mutational landscape and to evaluate the outcome of surgical treatment and ICI in SNMM in a real-world setting. Methods Thirty-eight SNMM patients being treated between 1999 and 2020 at our institution were retrospectively reviewed. Survival curves were generated according to Kaplan–Meier and compared by the log-rank test. Results Local failure was seen in 60% of patients treated in a curative intent. Overall, 24% of all patients suffered from regional and 66% from distant metastases. Next generation sequencing revealed mutations of BRAF, NRAS and KRAS. One out of three patients treated with a primary ICI showed a complete response (CR) and two showed progressive disease. Eleven patients received ICI as a palliative treatment. CR could be observed in three patients and stable disease in one patient. In the whole study population, the 5-year overall survival rate (OS) was 26%. OS was better for patients who received ICI during the course of disease. Conclusions Recurrences and distant metastases are frequent in SNMM. Durable CR could be observed after primary and palliative ICI. Therefore, ICI in a palliative, adjuvant or even neoadjuvant setting might play a promising role in SNMM therapy while targetable mutations are rarely detected.

show abstract

Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy

Cited by 4 publications

References 18 publications

Primary Mucosal Melanoma of the Lip With GNA11 Mutation in a 23-Year-Old Pregnant Woman

Primary Mucosal Melanoma of the Lip With GNA11 Mutation in a 23-Year-Old Pregnant Woman

RAGE Signaling in Melanoma Tumors

Multimodal treatment and immune checkpoint inhibition in sinonasal mucosal melanoma: real-world data of a retrospective, single-center study

Contact Info

Product

Resources

About